A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv2 Show 4 more changesShow less
    • Trial sites expanded: 0 → 8 locations
    • Primary completion date: Mar 29, 2030 to Apr 1, 2030
    • Secondary endpoints: 1 to 2
    • Collaborators expanded, about 6 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Dementia
1,989 trials monitored
See 106 trials at risk
Alzheimer's Disease
1,261 trials monitored
See 69 trials at risk
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
Trial Details
NCT Number NCT07502560
Lead Sponsor GlaxoSmithKline
Collaborators: Finnish Vaccine Research;, Dr Arto Palmu
Conditions
(from sponsor)		 Herpes Zoster
Related terms Alzheimer Disease, Herpes Zoster
Enrollment 33,609 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov